3.8 Article

Gout disease-specific quality of life and the association with gout characteristics

Journal

PATIENT-RELATED OUTCOME MEASURES
Volume 1, Issue -, Pages 1-8

Publisher

DOVE MEDICAL PRESS LTD
DOI: 10.2147/PROM.S8310

Keywords

Gout impact scale; GIS; patient-reported outcomes

Funding

  1. Takeda Pharmaceutical, Inc.
  2. University of California, San Diego General Clinical Research Center Program [M01 RR00827]
  3. National Center for Research Resources, National Institutes of Health
  4. VA Research Service
  5. National Institutes of Health Award [NIAMS K23 AR053858-01A1]
  6. TAP and Takeda pharmaceuticals
  7. Regeneron
  8. Research Service of the Department of Veterans Affairs and Takeda Pharmaceuticals
  9. Takeda Pharmaceuticals
  10. TAP pharmaceuticals
  11. NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR053858] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Purpose: Assess the association of gout characteristics with health-related quality of life (HRQoL) using a new gout-specific HRQoL instrument, the Gout Impact Scale (GIS). Patients and methods: Gout patients completed the GIS (five scales [0-100 score each] representing impact of gout overall [three scales] and during an attack [two scales]) and other questions describing recent gout attacks, treatment, gout history, comorbidities, and demographics. Physicians confirmed gout diagnosis, presence of tophi, and most recent serum uric acid (sUA) level. Relationships between gout characteristics and GIS scores were examined using analysis of variance and correlation analyses. Results: The majority of patients were male (90.2%) with a mean age of 62.2 (+/- 11.8) years. Approximately one-half (49.7%) reported >= 3 gout attacks in the past year and the majority (57.9%) reported experiencing gout-related pain between attacks. Patients had appreciable concern about their gout (gout concern overall scale, 63.1 +/- 28.0) but believed their treatment was adequate (unmet gout treatment need scale (38.2 +/- 21.4) below scale mid-point). Significantly worse GIS scores were associated with increasing attack frequency and greater amount of time with pain between attacks (most scales, P < 0.001). Common objective measures such as sUA level, presence of tophi and the number of joints involved in a typical attack did not appear to be good indicators of the impact of gout on the patients' HRQoL. Conclusion: Attack frequency and gout pain between attacks were important correlates of patients' ratings of gout impact on their HRQoL. Further studies are needed to determine the minimal important difference for each GIS scale and interpret our results relative to other patient populations with gout.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available